Averitas Drug Patent Portfolio
Averitas owns 1 orange book drug protected by 8 US patents Given below is the list of Averitas's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8821920 | Therapeutic patch for transdermal delivery of capsaicin | 26 Mar, 2030 | Active |
| US9226903 | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer | 15 Dec, 2028 | Active |
| US10034841 | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer | 06 Sep, 2025 | Active |
| US10463598 | Compositions and kits for the removal of irritating compounds from bodily surfaces | 05 Sep, 2023 | Expired |
| US10869827 | Compositions and kits for the removal of irritating compounds from bodily surfaces | 05 Sep, 2023 | Expired |
| US8263059 | Compositions and kits for the removal of irritating compounds from bodily surfaces | 05 Sep, 2023 | Expired |
| US8889113 | Compositions and kits for the removal of irritating compounds from bodily surfaces | 05 Sep, 2023 | Expired |
| US6239180 | Transdermal therapeutic device and method with capsaicin and capsaicin analogs | 06 Nov, 2016 | Expired |
Latest Legal Activities on Averitas's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Averitas.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 29 Apr, 2024 | US8263059 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Jun, 2023 | US9226903 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Apr, 2023 | US10463598 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 May, 2022 | US8889113 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Feb, 2022 | US8821920 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jan, 2022 | US10034841 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 22 Dec, 2020 | US10869827 |
|
Recordation of Patent Grant Mailed
Critical
| 22 Dec, 2020 | US10869827 |
|
Email Notification
Critical
| 03 Dec, 2020 | US10869827 |
|
Issue Notification Mailed
Critical
| 02 Dec, 2020 | US10869827 |
| Dispatch to FDC | 23 Nov, 2020 | US10869827 |
|
Application Is Considered Ready for Issue
Critical
| 17 Nov, 2020 | US10869827 |
|
Issue Fee Payment Received
Critical
| 13 Nov, 2020 | US10869827 |
|
Issue Fee Payment Verified
Critical
| 13 Nov, 2020 | US10869827 |
|
Electronic Review
Critical
| 18 Sep, 2020 | US10869827 |
Averitas's Family Patents
Averitas drugs have patent protection in a total of 29 countries. It's US patent count contributes only to 21.1% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Averitas Drug List
Given below is the complete list of Averitas's drugs and the patents protecting them.
1. Qutenza
Qutenza is protected by 8 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8821920 | Therapeutic patch for transdermal delivery of capsaicin |
26 Mar, 2030
(4 years from now)
| Active |
| US9226903 | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer |
15 Dec, 2028
(3 years from now)
| Active |
| US10034841 | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer |
06 Sep, 2025
(3 months from now)
| Active |
| US10463598 | Compositions and kits for the removal of irritating compounds from bodily surfaces |
05 Sep, 2023
(1 year, 8 months ago)
| Expired |
| US10869827 | Compositions and kits for the removal of irritating compounds from bodily surfaces |
05 Sep, 2023
(1 year, 8 months ago)
| Expired |
| US8263059 | Compositions and kits for the removal of irritating compounds from bodily surfaces |
05 Sep, 2023
(1 year, 8 months ago)
| Expired |
| US8889113 | Compositions and kits for the removal of irritating compounds from bodily surfaces |
05 Sep, 2023
(1 year, 8 months ago)
| Expired |
| US6239180 | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
06 Nov, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qutenza's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List